PHAR
Pharming Group·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
PHAR Profile
Pharming Group N.V.
A biotech company that develops protein replacement therapies and precision medicines
Pharmaceutical
11/11/1988
12/23/2020
NASDAQ Stock Exchange
404
12-31
Depository Receipts (Ordinary Shares)
Darwinweg 24, 2333 CR Leiden, The Netherlands
--
Pharming Group N.V. was established on November 11, 1988 as a private limited liability company under the laws of the Netherlands under the name GENFARM B.V.GENFARM B.V. The company is a global company that is developing new protein replacement drugs to meet the urgent needs of rare protein drugs for commercial treatment. The flagship of their portfolio is their recombinant human C1 esterase inhibitor (rhC1 INH) franchise. C1INH is a naturally occurring protein that controls swelling of affected tissue by down-regulating the complement cascade. Their lead product, RUCONEST, is the first and only plasma-free rhc1in protein replacement therapy. It is approved for the treatment of acute hereditary angioedema, or HAE onset. The company commercializes Rouconest in the US, the EU and the UK through its own sales and marketing organization, and in the rest of the world through its distribution network. The company is also developing rhC1INH for subsequent indications, including preeclampsia, acute kidney injury, and they are also studying the clinical efficacy of rhC1INH in COVID 19. In addition, the company is investigating their oral precision drug leniolisib (a phosphoinositol 3 kinase δ or PI3Kδ inhibitor) for the treatment of activated PI3K-delta syndrome, or APDS, in the US and European registration support phase 2/3 studies. In addition, the company is also using its GMO manufacturing technology to develop next-generation protein replacement therapies, especially for Pompe disease, which is still in the preclinical stage.
